JP5699149B2 - Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 - Google Patents

Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 Download PDF

Info

Publication number
JP5699149B2
JP5699149B2 JP2012528103A JP2012528103A JP5699149B2 JP 5699149 B2 JP5699149 B2 JP 5699149B2 JP 2012528103 A JP2012528103 A JP 2012528103A JP 2012528103 A JP2012528103 A JP 2012528103A JP 5699149 B2 JP5699149 B2 JP 5699149B2
Authority
JP
Japan
Prior art keywords
compound
ring
nitrogen
sulfur
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012528103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013503905A (ja
JP2013503905A5 (https=
Inventor
ダニエル エー． アーランソン，
ダニエル エー． アーランソン，
ダグ マーコッテ，
ダグ マーコッテ，
グナナサムバンダム クマラベル，
グナナサムバンダム クマラベル，
ジュンファ ファン，
ジュンファ ファン，
デピン ワン，
デピン ワン，
ジュリオ エイチ． キュアーボ，
ジュリオ エイチ． キュアーボ，
ローラ シルビアン，
ローラ シルビアン，
ノエル パウエル，
ノエル パウエル，
ミナ バイ，
ミナ バイ，
ブライアン ティー． ホプキンス，
ブライアン ティー． ホプキンス，
アート タベラス，
アート タベラス，
ビン グアン，
ビン グアン，
パトリック コンロン，
パトリック コンロン，
ミン ション，
ミン ション，
トレーシー ジェイ． ジェンキンス，
トレーシー ジェイ． ジェンキンス，
ダニエル スコット，
ダニエル スコット，
アレクセイ エー． ルゴフスコイ，
アレクセイ エー． ルゴフスコイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2013503905A publication Critical patent/JP2013503905A/ja
Publication of JP2013503905A5 publication Critical patent/JP2013503905A5/ja
Application granted granted Critical
Publication of JP5699149B2 publication Critical patent/JP5699149B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2012528103A 2009-09-04 2010-09-03 Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 Expired - Fee Related JP5699149B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24001109P 2009-09-04 2009-09-04
US61/240,011 2009-09-04
PCT/US2010/047883 WO2011029046A1 (en) 2009-09-04 2010-09-03 Bruton's tyrosine kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015027205A Division JP2015091898A (ja) 2009-09-04 2015-02-16 Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬

Publications (3)

Publication Number Publication Date
JP2013503905A JP2013503905A (ja) 2013-02-04
JP2013503905A5 JP2013503905A5 (https=) 2013-10-17
JP5699149B2 true JP5699149B2 (ja) 2015-04-08

Family

ID=43649668

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012528103A Expired - Fee Related JP5699149B2 (ja) 2009-09-04 2010-09-03 Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
JP2015027205A Withdrawn JP2015091898A (ja) 2009-09-04 2015-02-16 Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
JP2017137018A Expired - Fee Related JP6326533B2 (ja) 2009-09-04 2017-07-13 Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
JP2018078461A Expired - Fee Related JP6673969B2 (ja) 2009-09-04 2018-04-16 Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
JP2020000042A Withdrawn JP2020055871A (ja) 2009-09-04 2020-01-05 Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
JP2022033553A Pending JP2022071149A (ja) 2009-09-04 2022-03-04 Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015027205A Withdrawn JP2015091898A (ja) 2009-09-04 2015-02-16 Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
JP2017137018A Expired - Fee Related JP6326533B2 (ja) 2009-09-04 2017-07-13 Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
JP2018078461A Expired - Fee Related JP6673969B2 (ja) 2009-09-04 2018-04-16 Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
JP2020000042A Withdrawn JP2020055871A (ja) 2009-09-04 2020-01-05 Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
JP2022033553A Pending JP2022071149A (ja) 2009-09-04 2022-03-04 Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬

Country Status (15)

Country Link
US (7) US8785440B2 (https=)
EP (2) EP3461824B1 (https=)
JP (6) JP5699149B2 (https=)
CN (3) CN102711473B (https=)
AR (2) AR078320A1 (https=)
AU (3) AU2010289313B2 (https=)
CA (2) CA2771822C (https=)
DK (1) DK2473049T3 (https=)
ES (2) ES2711936T3 (https=)
HU (1) HUE043522T2 (https=)
NZ (1) NZ598985A (https=)
PL (1) PL2473049T3 (https=)
PT (1) PT2473049T (https=)
TW (2) TWI711610B (https=)
WO (1) WO2011029046A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015091898A (ja) * 2009-09-04 2015-05-14 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
KR20130113948A (ko) * 2010-05-17 2013-10-16 어레이 바이오파마 인크. Gpr119 조절제로서의 피페리디닐-치환된 락탐류
KR101541086B1 (ko) * 2010-08-20 2015-08-03 허치슨 메디파르마 리미티드 피롤로피리미딘 화합물 및 그 용도
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
MX354412B (es) 2011-06-10 2018-03-05 Merck Patent Gmbh Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
ES2548414T3 (es) * 2011-07-08 2015-10-16 Novartis Ag Novedosos derivados de pirrolo pirimidina
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
CA2851788C (en) 2011-10-11 2022-11-29 Dana-Farber Cancer Institute, Inc. Pyrazol-3-ones that activate pro-apoptotic bax
US9221809B2 (en) 2011-10-31 2015-12-29 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
EP2773639B1 (en) * 2011-11-03 2017-04-26 F. Hoffmann-La Roche AG Alkylated piperazine compounds as inhibitors of btk activity
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
MX2014005282A (es) * 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos de 8-fluoroftalazin-1 (2h) -ona.
MX2014005285A (es) * 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos biciclicos de piperazina.
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP3366685A1 (en) * 2012-01-09 2018-08-29 X-Chem, Inc. Tryptoline derivatives having kinase inhibitory activity and uses thereof
JP6182593B2 (ja) * 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
CN102702110A (zh) * 2012-05-24 2012-10-03 盛世泰科生物医药技术(苏州)有限公司 一种4-氨基-5,6-二氯嘧啶的制备方法
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
KR20150060839A (ko) * 2012-10-26 2015-06-03 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
KR101668574B1 (ko) * 2012-11-02 2016-10-24 화이자 인코포레이티드 브루톤 티로신 키나제 억제제
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
CA2902686C (en) 2013-04-25 2017-01-24 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors
WO2014210255A1 (en) 2013-06-26 2014-12-31 Abbvie Inc. Primary carboxamides as btk inhibitors
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
BR112016006978A2 (pt) 2013-09-30 2017-08-01 Pharmacyclics Llc inibidores de tirosina quinase de bruton
SI3077395T1 (en) 2013-12-05 2018-03-30 Pfizer Inc. Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
AU2014362231B2 (en) * 2013-12-11 2019-04-04 Biogen Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
CR20170077A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
EP3288943B1 (en) 2015-05-01 2022-09-28 Pfizer Inc. Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase
KR102404759B1 (ko) * 2016-05-16 2022-05-31 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. Ｂｔｋ 억제제로서의 5-아미노피라졸 카르복사미드 유도체 및 그것의 제조 방법 및 제약학적 조성물
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
JP7214632B2 (ja) * 2016-07-21 2023-01-30 バイオジェン エムエー インク． ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
WO2018033853A2 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
IL292938A (en) 2016-09-19 2022-07-01 Mei Pharma Inc Combined treatment
CA3045339A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
IL269933B (en) * 2017-04-14 2022-07-01 Biogen Ma Inc Benzozapine analogues as inhibitors for proton tyrosine kinase
WO2018204532A1 (en) 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
US11192865B2 (en) 2017-08-21 2021-12-07 Vivace Therapeutics, Inc. Benzosulfonyl compounds
CN107445981B (zh) * 2017-08-25 2018-06-22 牡丹江医学院 一种用于防治宫颈炎的活性化合物
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
US11524943B1 (en) 2017-12-06 2022-12-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
US11661403B2 (en) 2018-05-16 2023-05-30 Vivace Therapeutics, Inc. Oxadiazole compounds
CA3111126A1 (en) 2018-08-31 2020-03-05 Stichting Katholieke Universiteit Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof
SG11202101827RA (en) 2018-09-21 2021-04-29 Pfizer N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
CN109369513B (zh) * 2018-11-20 2020-08-25 都创(上海)医药科技有限公司 一种fbdd常用分子片段的制备方法
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
US20220249491A1 (en) 2019-06-10 2022-08-11 Beigene Switzerland Gmbh Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
CN113416847B (zh) * 2021-07-05 2022-05-31 昆明理工大学 一种将提钒尾渣资源化、减量化、无害化处理的方法
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
AU2023364628A1 (en) 2022-10-18 2025-04-03 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4528138A (en) 1984-06-20 1985-07-09 E. R. Squibb & Sons, Inc. 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en) * 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
IL151552A0 (en) 2000-03-17 2003-04-10 Bristol Myers Squibb Pharma Co Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
ATE423120T1 (de) 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
WO2003037271A2 (en) * 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
JP2005515173A (ja) 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド［４，５−ｂ］インドール誘導体
MXPA05007485A (es) * 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
UA92450C2 (ru) * 2003-01-14 2010-11-10 Арена Фармасьютикалз, Инк. 1,2,3-тризамещенные арильные и гетероарильные производные как модуляторы метаболизма, профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия
JP4845736B2 (ja) 2003-10-14 2011-12-28 アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ プロテインキナーゼ阻害剤
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
PT1812440E (pt) 2004-11-04 2011-01-25 Vertex Pharma Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
CN102633730A (zh) 2004-12-03 2012-08-15 先灵公司 作为cb1拮抗剂的取代哌嗪
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
WO2006071875A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
JP5191391B2 (ja) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
EP1965862A2 (en) 2005-12-21 2008-09-10 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
WO2008005368A2 (en) 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
WO2008014307A2 (en) 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008033858A2 (en) 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
DK2526933T3 (en) * 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
JP2010520199A (ja) 2007-03-02 2010-06-10 シェーリング コーポレイション ピペリジン誘導体およびその使用方法
CN101730699A (zh) 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
WO2008144253A1 (en) * 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
CN101932580B (zh) * 2007-06-01 2013-05-22 葛兰素史密丝克莱恩有限责任公司 咪唑并吡啶激酶抑制剂
PL2242749T3 (pl) 2008-02-05 2013-09-30 Hoffmann La Roche Nowe pirydynony i pirydazynony
JP2011519049A (ja) 2008-04-29 2011-06-30 イミューンエクサイト インコーポレイテッド 免疫調節組成物およびその使用方法
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8084620B2 (en) 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
EP3828185B1 (en) 2009-01-06 2024-11-20 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
KR20120016662A (ko) 2009-05-25 2012-02-24 산도즈 아게 세프토비프롤 메도카릴의 제조 방법
NZ598985A (en) * 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
US8685880B2 (en) 2010-06-30 2014-04-01 Chevron U.S.A. Inc. On-site drying of aqueous salt for ionic liquid make-up
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
US9353087B2 (en) * 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
AU2014362231B2 (en) * 2013-12-11 2019-04-04 Biogen Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
EP3444251B1 (en) * 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2016054627A1 (en) 2014-10-03 2016-04-07 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance
JP7214632B2 (ja) * 2016-07-21 2023-01-30 バイオジェン エムエー インク． ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
EP4313023A1 (en) * 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
WO2023081709A1 (en) * 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Vecabrutinib for the treatment of graft-versus-host disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015091898A (ja) * 2009-09-04 2015-05-14 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬

Also Published As

Publication number Publication date
JP2020055871A (ja) 2020-04-09
DK2473049T3 (en) 2019-04-01
JP2013503905A (ja) 2013-02-04
US20230046457A1 (en) 2023-02-16
PT2473049T (pt) 2019-03-04
CN112300172A (zh) 2021-02-02
AU2010289313B2 (en) 2016-05-19
NZ598985A (en) 2013-07-26
AR078320A1 (es) 2011-11-02
US10577374B2 (en) 2020-03-03
ES2711936T3 (es) 2019-05-08
TW201713640A (en) 2017-04-16
CN107011330B (zh) 2020-07-03
TW201120040A (en) 2011-06-16
US9249146B2 (en) 2016-02-02
CA2771822C (en) 2020-08-11
AR122069A2 (es) 2022-08-10
US20160376281A1 (en) 2016-12-29
US20200399283A1 (en) 2020-12-24
CA3082212C (en) 2023-03-07
US20120157443A1 (en) 2012-06-21
JP2017186373A (ja) 2017-10-12
CA2771822A1 (en) 2011-03-10
PL2473049T3 (pl) 2019-07-31
CN107011330A (zh) 2017-08-04
US8785440B2 (en) 2014-07-22
US20180065974A1 (en) 2018-03-08
EP2473049B1 (en) 2018-11-28
HUE043522T2 (hu) 2019-08-28
ES2891543T3 (es) 2022-01-28
US20240246988A1 (en) 2024-07-25
WO2011029046A1 (en) 2011-03-10
JP2015091898A (ja) 2015-05-14
AU2010289313A1 (en) 2012-04-12
AU2016202601B2 (en) 2017-12-07
JP2018111726A (ja) 2018-07-19
JP6673969B2 (ja) 2020-04-01
EP3461824A1 (en) 2019-04-03
CN112300172B (zh) 2024-01-16
TWI557127B (zh) 2016-11-11
JP6326533B2 (ja) 2018-05-16
CN102711473A (zh) 2012-10-03
AU2018201668A1 (en) 2018-04-05
CA3082212A1 (en) 2011-03-10
AU2018201668B2 (en) 2020-02-27
JP2022071149A (ja) 2022-05-13
EP2473049A4 (en) 2013-02-13
EP2473049A1 (en) 2012-07-11
EP3461824B1 (en) 2021-08-25
TWI711610B (zh) 2020-12-01
AU2016202601A1 (en) 2016-05-19
US9790229B2 (en) 2017-10-17
CN102711473B (zh) 2016-11-09
US20140309212A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
JP6326533B2 (ja) Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
HK40006080B (en) Bruton's tyrosine kinase inhibitors
HK40006080A (en) Bruton's tyrosine kinase inhibitors
HK1175943B (en) Bruton's tyrosine kinase inhibitors
HK1175943A (en) Bruton's tyrosine kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140808

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150216

R150 Certificate of patent or registration of utility model

Ref document number: 5699149

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees